Debt rising as profit falls
Total debt rose 180.1% while net profit fell 26.7% — worth checking how the balance sheet is being funded.
Importance 77 / 95 · financial health
The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.
Total debt rose 180.1% while net profit fell 26.7% — worth checking how the balance sheet is being funded.
Importance 77 / 95 · financial health
Revenue grew 2.2% but profit declined 26.7%, so the company kept less of each rupee of revenue as profit.
Importance 73 / 95 · growth
EBITDA margin dropped 5.0 percentage points in a single year, from 29.0% to 24.0% — worth investigating.
Importance 68 / 95 · anomaly
Classified by the exchange under Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals.
Peer set used on this page: 12 pharmaceuticals.
Revenue grew 9.7% a year over 4 years, from ₹13,092 cr in FY2022 to ₹18,980 cr in FY2026. Net profit grew 4.4% a year over the same period.
Revenue grew 2.2% but profit declined 26.7%, so the company kept less of each rupee of revenue as profit.
Rule PROFIT_SLOWER_THAN_REVENUE
Over 4 years profit compounded at 11.0% a year while revenue compounded at 6.7% a year — though FY2024 saw a one-off step-change of 47% (a merger, restructuring or a recovery off a low base), so the compounding is uneven.
Net profit fell 26.7% year on year (FY2025 → FY2026).
Revenue has compounded at 6.7% a year over 4 years (₹21,763 → ₹28,163) — steady rather than rapid.
In Q2 FY27 (Jul–Sep 2026), revenue was ₹7,404 cr (down 2.4% on the same quarter last year) and net profit ₹852 cr (down 37.1%).
Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.
Q2 FY27 net profit was ₹852 cr, down 37.1% from ₹1,353 cr a year earlier.
Rule QTR_PROFIT_GROWTH_YOY
Q2 FY27 net profit declined 37.1% while revenue declined 2.4% vs the same quarter last year — a gap of 34.6 percentage points.
Rule QTR_PROFIT_VS_REVENUE_GROWTH
Q2 FY27 EBIT was ₹1,194 cr, down 36.0% from ₹1,867 cr a year earlier.
Rule QTR_OPERATING_PERFORMANCE_CHANGE_YOY
| Quarter | Revenue | YoY | Net profit | YoY | Net margin |
|---|---|---|---|---|---|
| Q3 FY25 | 7,073 | +7.1% | 1,575 | +47.4% | 22.3% |
| Q4 FY25 | 6,730 | +9.2% | 1,214 | +30.3% | 18.0% |
| Q1 FY26 | 6,957 | +3.9% | 1,292 | +9.9% | 18.6% |
| Q2 FY26 | 7,589 | +7.6% | 1,353 | +3.7% | 17.8% |
| Q3 FY26 | 7,074 | +0.0% | 674 | −57.2% | 9.5% |
| Q4 FY26 | 6,541 | −2.8% | 543 | −55.3% | 8.3% |
| Q1 FY27 | 7,119 | +2.3% | 786 | −39.2% | 11.0% |
| Q2 FY27 | 7,404 | −2.4% | 852 | −37.1% | 11.5% |
Trailing twelve months to 30 Sept 2026 · sum of the last 4 contiguous quarters
EBITDA margin was 29.3% in FY2026, against 30.8% in FY2022. ROE was 10.6% and ROCE 14.8% in FY2026.
ROE declined from 18.1% to 11.7% year on year.
Rule ROE_DETERIORATED_YOY
EBITDA margin has ranged from 22.2% to 29.0% over 4 years and sits at 24.0% now.
It had little or no debt in FY2026 (debt-to-equity 0.00x). Operating cash flow was 0.81x net profit.
Total debt rose 180.1% while net profit fell 26.7% — worth checking how the balance sheet is being funded.
Rule DEBT_UP_EARNINGS_DOWN
Net worth compounded at 13.1% a year over 4 years (₹21,117 → ₹34,520).
Free cash flow has been positive in 5 of the last 5 years.
Within its 12-company Pharmaceuticals peer group, it ranks 9 of 12 on return on equity and 9 of 12 on EBITDA margin. Its P/E of 40.1 compares with a peer median of 45.3.
Ranked against 12 pharmaceuticals (FY2026, consolidated).
CIPLA · 12th of 12 · set median 14.8%
CIPLA · 9th of 12 · set median 28.7%
CIPLA · 9th of 12 · set median 14.4%
CIPLA · 4th of 12 · set median 45.3×
Trades at 3.31× book — 30% below the pharmaceuticals median of 4.74×.
Rule PB_BELOW_PEERS
On the trailing twelve months. Last full year: P/E 29.6× · P/S 3.9× · ROE 11.7%. TTM and full-year profit and EBITDA differ by more than 15% — a one-off in a recent quarter is moving the trailing figure; weigh it against the full year.
The share price is down 7.5% over 1 year, up 12.9% over 3 years (4.1% a year) and up 58.6% over 5 years (9.7% a year). These are price changes excluding dividends, adjusted for splits and bonuses, to 20 Nov 2026; it is 7.6% below its 52-week high.
Over 4 years profit compounded at 11.0% a year while the stock returned 4.1% a year — the FY2022 base was somewhat depressed, so part of this is recovery rather than trend.
Rule STOCK_LAGGED_EARNINGS · rebound
Price-action indicators as of 2026-11-20. Secondary to the fundamentals above — included for timing context, not as a signal.
Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.
The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 13,092 | 15,791 | 16,574 | 19,045 | 18,980 |
| Total income | 13,758 | 16,247 | 17,645 | 20,030 | 20,103 |
| EBITDA | 4,033 | 4,249 | 5,555 | 6,763 | 5,558 |
| Profit before tax | 3,546 | 3,441 | 4,947 | 6,469 | 4,636 |
| Net profit | 2,958 | 2,513 | 4,077 | 5,158 | 3,515 |
| EPS (₹) | 36.7 | 31.1 | 50.5 | 63.9 | 43.5 |
| Net worth | 22,514 | 24,638 | 27,974 | 32,099 | 34,201 |
| Total debt | 0 | 0 | 0 | 0 | 11 |
| Operating cash flow | 2,773 | 3,035 | 3,727 | 3,301 | 2,832 |
| Free cash flow | 2,479 | 2,479 | 3,206 | 2,754 | 2,060 |
| Ratio | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Growth | |||||
| Revenue growth YoY | — | 20.6 | 5.0 | 14.9 | -0.3 |
| Profit growth YoY | — | -15.0 | 62.2 | 26.5 | -31.8 |
| Profitability | |||||
| EBITDA margin % | 30.8 | 26.9 | 33.5 | 35.5 | 29.3 |
| Net margin % | 21.5 | 15.5 | 23.1 | 25.8 | 17.5 |
| Return on equity % | 13.1 | 10.7 | 15.5 | 17.2 | 10.6 |
| Return on capital % | 15.9 | 15.5 | 18.9 | 20.6 | 14.8 |
| Leverage & cash | |||||
| Debt to equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash flow ÷ profit | 0.94 | 1.21 | 0.91 | 0.64 | 0.81 |
| Current ratio | 4.22 | 4.95 | 5.19 | 5.77 | 4.63 |